Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microscope inside the lungs reveals hidden damage in two diseases

NCT ID NCT02556697

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study was stopped early, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could improve understanding of how lung damage occurs in scleroderma and emphysema, potentially leading to earlier diagnosis or better treatments.
What could go wrong
This was a very small, terminated study with only 9 participants, so results may be limited and not generalizable. The technique is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Nov 2014

Finished

May 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with scleroderma with diffuse interstitial pneumonia, indicating a bronchoscopy. * Patients with pulmonary emphysema indication for bronchoscopy. * Age greater than 18 years. * Having an affiliation to social security. * Signed informed consent. Exclusion Criteria: * Severe chronic respiratory insufficiency against-indicating the completion of a bronchoscopy * Hypercapnia defined by a PaCO2 ≥ 6 kPa * Disorders of hemostasis against-indicating performing a bronchoscopy * Anticoagulant therapy can not be interrupted time of completion of the examination * A history of pneumonectomy or contralateral exploration in a nonfunctional lung * Contraindication to the injection of fluorescein (including treatment with beta-blocker eye drops or po) or one of its excipients * History of an injection poorly tolerated fluorescein * A history of food allergy or drug known * Myocardial infarction \<1 month * Unstable angina * Pregnant or lactating woman, premenopausal women without adequate contraception * Person under guardianship * Patient participating in another trial / participating in another trial within 4 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung disorder pulmonary emphysema systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary disease Pulmonary emphysema

Contacts and locations

Locations

  • Rouen University Hospital

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.